keyword
MENU ▼
Read by QxMD icon Read
search

CSF and Alzheimer

keyword
https://www.readbyqxmd.com/read/29154286/clinic-based-validation-of-cerebrospinal-fluid-biomarkers-with-florbetapir-pet-for-diagnosis-of-dementia
#1
Ignacio Álvarez, Miquel Aguilar, Jose Manuel González, Montse Ysamat, Carles Lorenzo-Bosquet, Alvaro Alonso, Juan Pablo Tartari, Silvia Romero, Monica Diez-Fairen, Maria Carcel, Francisco Pujalte, Pau Pastor
BACKGROUND: Cerebrospinal fluid (CSF) biomarker studies have shown variable accuracy for diagnosis of Alzheimer's disease (AD); therefore, internal validation is recommended. OBJECTIVE: To investigate the correlation between CSF biomarkers and cerebral 18-Florbetapir positron emission tomography (Amyloid-PET) and calculate their sensitivity and specificity to obtain the optimal clinical cut-off points to diagnose the etiology of cognitive impairment. METHODS: We performed Amyloid-PET scans and CSF biomarker levels analyses in 68 subjects (50 with mild cognitive impairment, 11 with AD dementia, and 7 with non-AD dementia)...
November 14, 2017: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/29154285/prediction-of-alzheimer-s-dementia-in-patients-with-amnestic-mild-cognitive-impairment-in-clinical-routine-incremental-value-of-biomarkers-of-neurodegeneration-and-brain-amyloidosis-added-stepwise-to-cognitive-status
#2
Catharina Lange, Per Suppa, Uwe Pietrzyk, Marcus R Makowski, Lothar Spies, Oliver Peters, Ralph Buchert
The aim of this study was to evaluate the incremental benefit of biomarkers for prediction of Alzheimer's disease dementia (ADD) in mild cognitive impairment (MCI) when added stepwise in the order of their collection in clinical routine. The model started with cognitive status characterized by the ADAS-13 score. Hippocampus volume (HV), cerebrospinal fluid (CSF) phospho-tau (pTau), and the FDG t-sum score in an AD-meta region-of-interest were compared as neurodegeneration markers. CSF-Aβ1-42 was used as amyloidosis marker...
November 14, 2017: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/29154283/longitudinal-neuroimaging-analysis-in%C3%A2-mild-moderate-alzheimer-s-disease-patients-treated-with-plasma-exchange-with%C3%A2-5-human-albumin
#3
Gemma Cuberas-Borrós, Isabel Roca, Mercè Boada, Lluís Tárraga, Isabel Hernández, Mar Buendia, Lourdes Rubio, Gustavo Torres, Ángel Bittini, Juan A Guzmán-de-Villoria, Francesc Pujadas, Mireia Torres, Laura Núñez, Joan Castell, Antonio Páez
BACKGROUND: Recently, modifications of Aβ1-42 levels in CSF and plasma associated with improvement in memory and language functions have been observed in patients with mild-moderate Alzheimer's disease (AD) treated with plasma exchange (PE) with albumin replacement. OBJECTIVE: To detect structural and functional brain changes in PE-treated AD patients as part of a Phase II clinical trial. METHODS: Patients received between 3 and 18 PE with albumin (Albutein® 5%, Grifols) or sham-PE (controls) for 21 weeks (divided in one intensive and two maintenance periods) followed by 6-month follow-up...
November 17, 2017: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/29154278/effects-of-physical-exercise-on-alzheimer-s-disease-biomarkers-a-systematic-review-of-intervention-studies
#4
Kristian Steen Frederiksen, Le Gjerum, Gunhild Waldemar, Steen Gregers Hasselbalch
Physical exercise may be an important adjunct to pharmacological treatment of Alzheimer's disease (AD). Animal studies indicate that exercise may be disease modifying through several mechanisms including reduction of AD pathology. We carried out a systematic review of intervention studies of physical exercise with hippocampal volume (on MRI), amyloid-β, total tau, phosphorylated tau in cerebrospinal fluid (CSF), 18F-FDG-PET or amyloid PET as outcome measures in healthy subjects, patients with subjective memory complaints, mild cognitive impairment, or AD...
November 16, 2017: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/29154275/association-of-cerebrospinal-fluid-csf-insulin-with-cognitive-performance-and-csf-biomarkers-of-alzheimer-s-disease
#5
Stefan L C Geijselaers, Pauline Aalten, Inez H G B Ramakers, Peter Paul De Deyn, Annemieke C Heijboer, Huiberdina L Koek, Marcel G M OldeRikkert, Janne M Papma, Fransje E Reesink, Lieke L Smits, Coen D A Stehouwer, Charlotte E Teunissen, Frans R J Verhey, Wiesje M van der Flier, Geert Jan Biessels
BACKGROUND: Abnormal insulin signaling in the brain has been linked to Alzheimer's disease (AD). OBJECTIVE: To evaluate whether cerebrospinal fluid (CSF) insulin levels are associated with cognitive performance and CSF amyloid-β and Tau. Additionally, we explore whether any such association differs by sex or APOE ɛ4 genotype. METHODS: From 258 individuals participating in the Parelsnoer Institute Neurodegenerative Diseases, a nationwide multicenter memory clinic population, we selected 138 individuals (mean age 66±9 years, 65...
November 16, 2017: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/29143217/fluid-biomarker-agreement-and-interrelation-in-dementia-due-to-alzheimer-s-disease
#6
Panagiotis Alexopoulos, Jennifer Roesler, Lukas Werle, Nathalie Thierjung, Iliana Lentzari, Marion Ortner, Timo Grimmer, Nikolaos Laskaris, Antonios Politis, Philippos Gourzis, Alexander Kurz, Robert Perneczky
The cerebrospinal fluid (CSF) levels of β-amyloid 42, total tau, and phosphorylated tau 181 are supposed to be all continuously abnormal in dementia due to Alzheimer's disease (AD), being the most advanced disease stage. The aim of the present study, which included a monocentric and a multicentric sample (N = 119 and 178, respectively), was to investigate the degree of CSF biomarker agreement and interrelation in AD dementia. Based on previously published cut-off values, biomarker values were categorized as positive or negative for AD (dichotomization strategy) and as either positive, negative, or borderline (trichotomization strategy)...
November 15, 2017: Journal of Neural Transmission
https://www.readbyqxmd.com/read/29142140/imaging-and-csf-analyses-effectively-distinguish-cjd-from-its-mimics
#7
Peter Rudge, Harpreet Hyare, Alison Green, John Collinge, Simon Mead
OBJECTIVE: To review clinical and investigation findings in patients referred to a specialist prion clinic who were suspected to have sporadic Creutzfeldt-Jakob disease (sCJD) and yet were found to have an alternative final diagnosis. METHODS: Review the clinical findings and investigations in 214 patients enrolled into the UK National Prion Monitoring Cohort Study between October 2008 and November 2015 who had postmortem confirmed sCJD and compare these features with 50 patients referred over the same period who had an alternative final diagnosis (CJD mimics)...
November 15, 2017: Journal of Neurology, Neurosurgery, and Psychiatry
https://www.readbyqxmd.com/read/29142138/chitotriosidase-chit1-is-increased-in-microglia-and-macrophages-in-spinal-cord-of-amyotrophic-lateral-sclerosis-and-cerebrospinal-fluid-levels-correlate-with-disease-severity-and-progression
#8
Petra Steinacker, Federico Verde, Lubin Fang, Emily Feneberg, Patrick Oeckl, Sigrun Roeber, Sarah Anderl-Straub, Adrian Danek, Janine Diehl-Schmid, Klaus Fassbender, Klaus Fliessbach, Hans Foerstl, Armin Giese, Holger Jahn, Jan Kassubek, Johannes Kornhuber, G Bernhard Landwehrmeyer, Martin Lauer, Elmar Hans Pinkhardt, Johannes Prudlo, Angela Rosenbohm, Anja Schneider, Matthias L Schroeter, Hayrettin Tumani, Christine A F von Arnim, Jochen Weishaupt, Patrick Weydt, Albert C Ludolph, Deniz Yilmazer Hanke, Markus Otto
OBJECTIVES: Neurochemical markers of amyotrophic lateral sclerosis (ALS) that reflect underlying disease mechanisms might help in diagnosis, staging and prediction of outcome. We aimed at determining the origin and differential diagnostic and prognostic potential of the putative marker of microglial activation chitotriosidase (CHIT1). METHODS: Altogether 316 patients were included, comprising patients with sporadic ALS, ALS mimics (disease controls (DCo)), frontotemporal lobar degeneration (FTLD), Creutzfeldt-Jakob disease (CJD), Alzheimer's disease (AD), Parkinson's disease (PD) and healthy controls (Con)...
November 15, 2017: Journal of Neurology, Neurosurgery, and Psychiatry
https://www.readbyqxmd.com/read/29136123/amyloid-network-topology-characterizes-the-progression-of-alzheimer-s-disease-during-the-predementia-stages
#9
Joana B Pereira, Tor Olof Strandberg, Sebastian Palmqvist, Giovanni Volpe, Danielle van Westen, Eric Westman, Oskar Hansson
There is increasing evidence showing that the accumulation of the amyloid-β (Aβ) peptide into extracellular plaques is a central event in Alzheimer's disease (AD). These abnormalities can be detected as lowered levels of Aβ42 in the cerebrospinal fluid (CSF) and are followed by increased amyloid burden on positron emission tomography (PET) several years before the onset of dementia. The aim of this study was to assess amyloid network topology in nondemented individuals with early stage Aβ accumulation, defined as abnormal CSF Aβ42 levels and normal Florbetapir PET (CSF+/PET-), and more advanced Aβ accumulation, defined as both abnormal CSF Aβ42 and Florbetapir PET (CSF+/PET+)...
November 9, 2017: Cerebral Cortex
https://www.readbyqxmd.com/read/29129937/cerebrospinal-fluid-proteins-as-regulators-of-beta-amyloid-aggregation-and-toxicity
#10
Kayla M Pate, Regina M Murphy
Amyloid disorders, such as Alzheimer's, are almost invariably late-onset diseases. One defining diagnostic feature of Alzheimer's disease is the deposition of beta-amyloid as extracellular plaques, primarily in the hippocampus. This raises the question: are there natural protective agents that prevent beta-amyloid from depositing, and is it loss of this protection that leads to onset of disease? Proteins in cerebrospinal fluid (CSF) have been suggested to act as just such natural protective agents. Here, we describe some of the early evidence that led to this suggestion, and we discuss, in greater detail, two CSF proteins that have garnered the bulk of the attention...
July 2017: Israel Journal of Chemistry
https://www.readbyqxmd.com/read/29128987/comparison-of-olfactory-and-gustatory-disorders-in-alzheimer-s-disease
#11
Minoru Kouzuki, Tetsuya Suzuki, Masaya Nagano, Syouta Nakamura, Yuto Katsumata, Ayumi Takamura, Katsuya Urakami
Patients with Alzheimer's disease (AD) develop olfactory and gustatory disorders. However, the order of failure and relevance of the pathophysiology are unclear. We compared olfactory identification and whole mouth gustation in patients with AD to those with mild cognitive impairment (MCI) and to healthy controls (HC) and assessed correlations with pathophysiology. Patients with AD (n = 40), MCI (n = 34), and HC (n = 40) were recruited. We performed the Odor Stick Identification Test for Japanese (OSIT-J), gustatory test by the intraoral dropping method using taste solutions, Mini-Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale-cognitive subscale Japanese version (ADAS-J cog), Touch Panel-type Dementia Assessment Scale (TDAS), and measurement of amyloid β (Aβ) 42 and phosphorylated tau (p-tau) 181 levels in cerebrospinal fluid (CSF)...
November 11, 2017: Neurological Sciences
https://www.readbyqxmd.com/read/29128930/prognostic-value-of-amyloid-pet-scan-in-normal-pressure-hydrocephalus
#12
Hyemin Jang, Seong Beom Park, Yeshin Kim, Ko Woon Kim, Jung Il Lee, Sung Tae Kim, Kyung Han Lee, Eun-Suk Kang, Yeong Sim Choe, Sang Won Seo, Hee Jin Kim, Yeo Jin Kim, Cindy W Yoon, Duk L Na
Amyloid positron emission tomography ([18F] florbetaben (FBB) PET) can be used to determine concomitant Alzheimer's disease (AD) in idiopathic normal pressure hydrocephalus (iNPH) patients. FBB PET scans and the tap test were performed in 31 patients with clinically suspected iNPH, and amyloid positive (iNPH/FBB+) and negative (iNPH/FBB-) groups were compared with respect to clinical characteristics. We evaluated prognostic value of FBB PET scans by analyzing the response to the tap test using a linear mixed model...
November 11, 2017: Journal of Neurology
https://www.readbyqxmd.com/read/29126887/combined-administration-of-resolvin-e1-and-lipoxin-a4-resolves-inflammation-in-a-murine-model-of-alzheimer-s-disease
#13
Alpdogan Kantarci, Nurgul Aytan, Iro Palaska, Danielle Stephens, Leah Crabtree, Claudia Benincasa, Bruce G Jenkins, Isabel Carreras, Alpaslan Dedeoglu
Dysfunction in the resolution of inflammation may play a key role in Alzheimer's disease (AD). In this study, we found that the levels of specialized pro-resolving lipid mediators (SPMs) in the hippocampus of 5xFAD mice are significantly lower than in non-transgenic littermates. We, therefore, tested the hypothesis that treatment with resolvin E1 (RvE1) and lipoxin A4 (LXA4) alone or in combination will reverse the neuroinflammatory process and decrease Aβ pathology. 5xFAD mice were treated intraperitoneally starting at 1month of age with RvE1 or LXA4 alone or in combination at a dose of 1...
November 7, 2017: Experimental Neurology
https://www.readbyqxmd.com/read/29126445/ykl-40-in-the-brain-and-cerebrospinal-fluid-of-neurodegenerative-dementias
#14
Franc Llorens, Katrin Thüne, Waqas Tahir, Eirini Kanata, Daniela Diaz-Lucena, Konstantinos Xanthopoulos, Eleni Kovatsi, Catharina Pleschka, Paula Garcia-Esparcia, Matthias Schmitz, Duru Ozbay, Susana Correia, Ângela Correia, Ira Milosevic, Olivier Andréoletti, Natalia Fernández-Borges, Ina M Vorberg, Markus Glatzel, Theodoros Sklaviadis, Juan Maria Torres, Susanne Krasemann, Raquel Sánchez-Valle, Isidro Ferrer, Inga Zerr
BACKGROUND: YKL-40 (also known as Chitinase 3-like 1) is a glycoprotein produced by inflammatory, cancer and stem cells. Its physiological role is not completely understood but YKL-40 is elevated in the brain and cerebrospinal fluid (CSF) in several neurological and neurodegenerative diseases associated with inflammatory processes. Yet the precise characterization of YKL-40 in dementia cases is missing. METHODS: In the present study, we comparatively analysed YKL-40 levels in the brain and CSF samples from neurodegenerative dementias of different aetiologies characterized by the presence of cortical pathology and disease-specific neuroinflammatory signatures...
November 10, 2017: Molecular Neurodegeneration
https://www.readbyqxmd.com/read/29125490/plasma-proteomic-profiles-of-cerebrospinal-fluid-defined-alzheimer-s-disease-pathology-in-older-adults
#15
Loïc Dayon, Jérôme Wojcik, Antonio Núñez Galindo, John Corthésy, Ornella Cominetti, Aikaterini Oikonomidi, Hugues Henry, Eugenia Migliavacca, Gene L Bowman, Julius Popp
BACKGROUND: Cerebrospinal fluid (CSF) biomarkers of the beta-amyloid and microtubule associated protein tau metabolism have proven the capacity to improve classification of subjects developing Alzheimer's disease (AD). The blood plasma proteome was characterized to further elaborate upon the mechanisms involved and identify proteins that may improve classification of older adults developing an AD dementia. OBJECTIVE: Identify and describe plasma protein expressions that best classify subjects with CSF-defined presence of AD pathology and cerebral amyloidosis...
2017: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/29125485/cognitive-variability-predicts-incident-alzheimer-s-disease-and-mild-cognitive-impairment-comparable-to-a-cerebrospinal-fluid-biomarker
#16
Carey E Gleason, Derek Norton, Eric D Anderson, Michelle Wahoske, Danielle T Washington, Emre Umucu, Rebecca L Koscik, N Maritza Dowling, Sterling C Johnson, Cynthia M Carlsson, Sanjay Asthana
BACKGROUND: Alzheimer's disease (AD) biomarkers are emerging as critically important for disease detection and monitoring. Most biomarkers are obtained through invasive, resource-intense procedures. A cognitive marker, intra-individual cognitive variability (IICV) may provide an alternative or adjunct marker of disease risk for individuals unable or disinclined to undergo lumbar puncture. OBJECTIVE: To contrast risk of incident AD and mild cognitive impairment (MCI) associated with IICV to risk associated with well-established biomarkers: cerebrospinal fluid (CSF) phosphorylated tau protein (p-tau181) and amyloid-β 42 (Aβ42) peptide...
November 8, 2017: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/29125327/obstructive-sleep-apnea-severity-affects-amyloid-burden-in-cognitively-normal-elderly-a-longitudinal-study
#17
Ram A Sharma, Andrew W Varga, Omonigho M Bubu, Elizabeth Pirraglia, Korey Kam, Ankit Parekh, Margaret Wohlleber, Margo D Miller, Andreia Andrade, Clifton Lewis, Samuel Tweardy, Maja Buj, Po L Yau, Reem Sadda, Lisa Mosconi, Yi Li, Tracy Butler, Lidia Glodzik, Els Fieremans, James S Babb, Kaj Blennow, Henrik Zetterberg, Shou E Lu, Sandra G Badia, Sergio Romero, Ivana Rosenzweig, Nadia Gosselin, Girardin Jean-Louis, David M Rapoport, Mony J de Leon, Indu Ayappa, Ricardo S Osorio
RATIONALE: Recent evidence suggests that Obstructive Sleep Apnea (OSA) may be a risk factor for developing Mild Cognitive Impairment and Alzheimer's disease. However, how sleep apnea affects longitudinal risk for Alzheimer's disease is less well understood. OBJECTIVE: To test the hypothesis that there is an association between severity of OSA and longitudinal increase in amyloid burden in cognitively normal elderly. METHODS: Data was derived from a 2-year prospective longitudinal study that sampled community-dwelling healthy cognitively normal elderly...
November 10, 2017: American Journal of Respiratory and Critical Care Medicine
https://www.readbyqxmd.com/read/29114370/taming-alzheimer-s-disease-new-perspectives-newer-horizons
#18
REVIEW
Debraj Sen, Anusree Majumder, Vijinder Arora, Neha Yadu, Ritwik Chakrabarti
Alzheimer's disease (AD) is the leading cause of dementia. However, current therapies do not prevent progression of the disease. New research into the pathogenesis of the disease has brought about a greater understanding of the "amyloid cascade" and associated receptor abnormalities, the role of genetic factors, and revealed that the disease process commences 10 to 20 years prior to the appearance of clinical signs. This greater understanding of the disease has prompted development of novel disease-modifying therapies (DMTs) which may prevent onset or delay progression of the disease...
July 6, 2017: Iranian Journal of Neurology
https://www.readbyqxmd.com/read/29111028/csf-biomarkers-%C3%AE-amyloid-tau-proteins-and-a-synuclein-in-the-differential-diagnosis-of-parkinson-plus-syndromes
#19
Vasilios C Constantinides, George P Paraskevas, Evangelia Emmanouilidou, Olga Petropoulou, Anastasia Bougea, Kostas Vekrellis, Ioannis Evdokimidis, Eleftherios Stamboulis, Elisabeth Kapaki
INTRODUCTION: Differential diagnosis of Parkinson-plus patients (PSP, CBD, MSA) and Parkinson's disease (PD) patients is often not straightforward, particularly in atypical cases or at the initial stages of the diseases. Classic CSF biomarkers (amyloid-beta - Aβ42, tau protein - τT and phosphorylated tau protein - τP-181) are established biomarkers in the diagnosis of Alzheimer's disease (AD). CSF a-synuclein (α-syn) has emerged as a promising biomarker in patients with Parkinsonism...
November 15, 2017: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/29102244/an-uhplc-ms-ms-method-for-simultaneous-quantification-of-human-amyloid-beta-peptides-a%C3%AE-1-38-a%C3%AE-1-40-and-a%C3%AE-1-42-in-cerebrospinal-fluid-using-micro-elution-solid-phase-extraction
#20
Ping-Ping Lin, Wei-Li Chen, Fei Yuan, Lei Sheng, Yu-Jia Wu, Wei-Wei Zhang, Guo-Qing Li, Hong-Rong Xu, Xue-Ning Li
Amyloid beta (Aβ) peptides in cerebrospinal fluid are extensively estimated for identification of Alzheimer's disease (AD) as diagnostic biomarkers. Unfortunately, their pervasive application is hampered by interference from Aβ propensity of self-aggregation, nonspecifically bind to surfaces and matrix proteins, and by lack of quantitive standardization. Here we report on an alternative Ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) method for simultaneous measurement of human amyloid beta peptides Aβ1-38, Aβ1-40 and Aβ1-42 in cerebrospinal fluid (CSF) using micro-elution solid phase extraction (SPE)...
October 23, 2017: Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
keyword
keyword
81816
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"